Tradipitant
Vanda Pharmaceuticals Rejects Cycle’s Second Takeover Bid Amid FDA Rejection of Tradipitant
Vanda Pharmaceuticals, Cycle Pharmaceuticals, takeover bid, FDA rejection, tradipitant, gastroparesis, biopharma, acquisition offer
Vanda Pharmaceuticals Receives FDA Rejection for Gastroparesis Treatment, Criticizes Agency’s Decision
Vanda Pharmaceuticals, FDA rejection, gastroparesis treatment, tradipitant, conclusory refusal